Vulvovaginalcandidiasis: species distribution, fluconazole resistance and drug efflux pump gene overexpression

In Vitro Fluconazole Susceptibility of 1,903 Clinical Isolates of Candida albicans and the Identification of ERG11 Mutations

(2013) Ying Ying et al.   Microbial Drug Resistance

Distribución de especies y perfil de susceptibilidad de aislados de Candida spp: la importancia de vigilar también cepas de la comunidad

(2013) Claudio Alburquenque et al.   Revista Chilena de Infectologia

Efficacy of Fluconazole and Nystatin in the Treatment of Vaginal Candida Species

(2012) MEL Consolaro et al.   ACTA DERMATO-VENEREOLOGICA

Correlation between Azole Susceptibilities, Genotypes, and ERG11 Mutations in Candida albicans Isolates Associated with Vulvovaginal Candidiasis in China

(2010) S.-H. Ge et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of risk factors in patients with vulvovaginal candidiasis and the value of chromID Candida agar versus CHROMagar Candida for recovery and presumptive identification of vaginal yeast species

(2010) Ahmet Bariş Guzel et al.   MEDICAL MYCOLOGY

In Vitro Susceptibility of a Large Collection of Candida Strains Against Fluconazole and Voriconazole by Using the CLSI Disk Diffusion Assay

(2010) Ana Carolina Azevedo et al.   MYCOPATHOLOGIA

Vulvovaginal Candidiasis Caused by Non-albicans Candida Species: New Insights

(2010) Melissa A. Kennedy et al.   Current Infectious Disease Reports

Transcriptional Activation and Increased mRNA Stability Contribute to Overexpression of CDR1 in Azole-Resistant Candida albicans

(2008) R. Manoharlal et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations

(2008) Y. Xu et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY